{"id":"https://openalex.org/W2075864291","doi":"https://doi.org/10.1046/j.1525-1411.2001.32007.x","title":"A Phase II Trial of Humanized Anti\u2010Vascular Endothelial Growth Factor Antibody for the Treatment of Androgen\u2010Independent Prostate Cancer","display_name":"A Phase II Trial of Humanized Anti\u2010Vascular Endothelial Growth Factor Antibody for the Treatment of Androgen\u2010Independent Prostate Cancer","publication_year":2001,"publication_date":"2001-04-01","ids":{"openalex":"https://openalex.org/W2075864291","doi":"https://doi.org/10.1046/j.1525-1411.2001.32007.x","mag":"2075864291"},"language":"en","primary_location":{"id":"doi:10.1046/j.1525-1411.2001.32007.x","doi":"https://doi.org/10.1046/j.1525-1411.2001.32007.x","is_oa":false,"landing_page_url":"https://doi.org/10.1046/j.1525-1411.2001.32007.x","pdf_url":null,"source":{"id":"https://openalex.org/S119077848","display_name":"The Prostate Journal","issn_l":"1095-5100","issn":["1095-5100","1525-1411"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Prostate Journal","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5009958250","display_name":"David Reese","orcid":"https://orcid.org/0000-0001-5293-6175","observed_orcids":["https://orcid.org/0000-0001-5293-6175"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David\u2003M. Reese","raw_affiliation_strings":["Department of Medicine, Division of Hematology-Oncology, Urologic Oncology Program, University of California, San Francisco, California, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Division of Hematology-Oncology, Urologic Oncology Program, University of California, San Francisco, California, U.S.A","institution_ids":["https://openalex.org/I180670191"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030098441","display_name":"Paige Fratesi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paige Fratesi","raw_affiliation_strings":["Department of Medicine, Division of Hematology-Oncology, Urologic Oncology Program, University of California, San Francisco, California, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Division of Hematology-Oncology, Urologic Oncology Program, University of California, San Francisco, California, U.S.A","institution_ids":["https://openalex.org/I180670191"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085340248","display_name":"Michelle Corry","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michelle Corry","raw_affiliation_strings":["Department of Medicine, Division of Hematology-Oncology, Urologic Oncology Program, University of California, San Francisco, California, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Division of Hematology-Oncology, Urologic Oncology Program, University of California, San Francisco, California, U.S.A","institution_ids":["https://openalex.org/I180670191"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060799552","display_name":"William F. Novotny","orcid":"https://orcid.org/0009-0000-3857-9829","observed_orcids":["https://orcid.org/0009-0000-3857-9829"]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William Novotny","raw_affiliation_strings":["Genentech, Inc., South San Francisco, California, U.S.A","\u2021Genentech, Incorporated, South San Francisco, California, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, California, U.S.A","institution_ids":["https://openalex.org/I183934855"]},{"raw_affiliation_string":"\u2021Genentech, Incorporated, South San Francisco, California, U.S.A","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112033205","display_name":"Eric B. Holmgren","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eric Holmgren","raw_affiliation_strings":["Genentech, Inc., South San Francisco, California, U.S.A","\u2021Genentech, Incorporated, South San Francisco, California, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, California, U.S.A","institution_ids":["https://openalex.org/I183934855"]},{"raw_affiliation_string":"\u2021Genentech, Incorporated, South San Francisco, California, U.S.A","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5007578304","display_name":"Eric Jay Small","orcid":"https://orcid.org/0000-0003-3191-6268","observed_orcids":["https://orcid.org/0000-0003-3191-6268"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Eric\u2003J. Small","raw_affiliation_strings":["Department of Medicine, Division of Hematology-Oncology, Urologic Oncology Program, University of California, San Francisco, California, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Division of Hematology-Oncology, Urologic Oncology Program, University of California, San Francisco, California, U.S.A","institution_ids":["https://openalex.org/I180670191"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5007578304"],"corresponding_institution_ids":["https://openalex.org/I180670191"],"apc_list":null,"apc_paid":null,"fwci":1.4384,"has_fulltext":false,"cited_by_count":68,"citation_normalized_percentile":{"value":0.82545371,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":98},"biblio":{"volume":"3","issue":"2","first_page":"65","last_page":"70"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.7592999935150146,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.7592999935150146,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.2328999936580658,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/anti-vegf-monoclonal-antibody","display_name":"anti-VEGF monoclonal antibody","score":0.8669999837875366},{"id":"https://openalex.org/keywords/castration-resistant-prostate-cancer","display_name":"castration-resistant prostate cancer","score":0.8769999742507935},{"id":"https://openalex.org/keywords/metastatic-prostate-cancer","display_name":"metastatic prostate cancer","score":0.9769999980926514},{"id":"https://openalex.org/keywords/tumor-angiogenesis","display_name":"tumor angiogenesis","score":0.9210000038146973},{"id":"https://openalex.org/keywords/psa-response","display_name":"PSA response","score":0.6700000166893005},{"id":"https://openalex.org/keywords/hyponatremia","display_name":"hyponatremia","score":0.8420000076293945},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.6460000276565552},{"id":"https://openalex.org/keywords/monotherapy","display_name":"monotherapy","score":0.6340000033378601}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8948336243629456},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.7274911403656006},{"id":"https://openalex.org/C2777025900","wikidata":"https://www.wikidata.org/wiki/Q29725","display_name":"Vascular endothelial growth factor","level":3,"score":0.6455010175704956},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.573209285736084},{"id":"https://openalex.org/C2780394083","wikidata":"https://www.wikidata.org/wiki/Q539568","display_name":"Angiogenesis","level":2,"score":0.5601097941398621},{"id":"https://openalex.org/C2781406297","wikidata":"https://www.wikidata.org/wiki/Q409450","display_name":"Prostate-specific antigen","level":4,"score":0.4898964762687683},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.48220908641815186},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.363214910030365},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3385775685310364},{"id":"https://openalex.org/C167734588","wikidata":"https://www.wikidata.org/wiki/Q4356503","display_name":"VEGF receptors","level":2,"score":0.20973321795463562}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1046/j.1525-1411.2001.32007.x","doi":"https://doi.org/10.1046/j.1525-1411.2001.32007.x","is_oa":false,"landing_page_url":"https://doi.org/10.1046/j.1525-1411.2001.32007.x","pdf_url":null,"source":{"id":"https://openalex.org/S119077848","display_name":"The Prostate Journal","issn_l":"1095-5100","issn":["1095-5100","1525-1411"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Prostate Journal","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320332193","display_name":"Genentech","ror":"https://ror.org/04gndp242"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":20,"referenced_works":["https://openalex.org/W1776913920","https://openalex.org/W1835232554","https://openalex.org/W1854708637","https://openalex.org/W1886850372","https://openalex.org/W1893347245","https://openalex.org/W1900061753","https://openalex.org/W1968306692","https://openalex.org/W1969328947","https://openalex.org/W1983622721","https://openalex.org/W1985712533","https://openalex.org/W1991355732","https://openalex.org/W2002268410","https://openalex.org/W2014604539","https://openalex.org/W2042555007","https://openalex.org/W2049972026","https://openalex.org/W2054822632","https://openalex.org/W2118881364","https://openalex.org/W2145224595","https://openalex.org/W2150908379","https://openalex.org/W2151232297"],"related_works":["https://openalex.org/W2159527770","https://openalex.org/W2978707713","https://openalex.org/W2161833993","https://openalex.org/W2145224595","https://openalex.org/W2121432337","https://openalex.org/W1975936849","https://openalex.org/W2167780425","https://openalex.org/W1886850372","https://openalex.org/W2803600261","https://openalex.org/W2023103815"],"abstract_inverted_index":{"ABSTRACT":[0],"Objective:":[1],"Vascular":[2],"endothelial":[3],"growth":[4],"factor":[5],"(VEGF)":[6],"is":[7,11,21],"a":[8,22,82,118,135,144,155],"glycoprotein":[9],"that":[10,27,209],"important":[12],"in":[13,35,50,121,186,195,213,226,235,250],"promoting":[14],"tumor":[15,37,100],"angiogenesis.":[16],"Recombinant":[17],"humanized":[18,23],"anti":[19],"(rhuMAb)\u2010VEGF":[20],"murine":[24],"monoclonal":[25],"antibody":[26],"neutralizes":[28],"VEGF":[29,49,64,203,212],"activity":[30],"and":[31,44,150,169,216],"has":[32],"shown":[33],"promise":[34],"animal":[36],"models.":[38],"Methods:":[39],"To":[40],"evaluate":[41,248],"the":[42,93,170,199],"efficacy":[43],"safety":[45],"of":[46,92,138,148,158,189,232],"single\u2010agent":[47,210],"rhuMAb":[48,63,202,211],"metastatic":[51],"androgen\u2010independent":[52],"prostate":[53,123,238],"cancer":[54,239],"(AIPC),":[55],"we":[56],"treated":[57],"15":[58,94,190],"patients":[59,79,95,132,141,152,227,236],"with":[60,183,201,217,228,237,252],"10":[61],"mg/kg":[62],"every":[65],"14":[66],"days":[67],"for":[68,77,99],"six":[69],"infusions":[70],"(one":[71],"cycle),":[72],"followed":[73],"by":[74],"additional":[75],"treatment":[76],"selected":[78],"who":[80,96],"had":[81,102,134,143,154],"response":[83,101],"or":[84,106,246],"were":[85,97,113],"stable.":[86],"Results:":[87],"After":[88],"one":[89,129],"cycle,":[90],"none":[91],"evaluable":[98],"an":[103],"objective":[104,164,224],"complete":[105],"partial":[107],"response.":[108],"Three":[109],"possible":[110],"mixed":[111],"responses":[112,225],"observed.":[114],"No":[115],"patient":[116],"achieved":[117],">50%":[119],"decrease":[120],"serum":[122],"specific":[124],"antigen":[125],"(PSA)":[126],"level":[127,146],"after":[128],"cycle.":[130],"Four":[131],"(27%)":[133],"PSA":[136,145,156,174],"decline":[137],"<50%,":[139,149],"three":[140],"(20%)":[142],"increase":[147,157],"eight":[151],"(53%)":[153],">50%.":[159],"The":[160],"median":[161,171],"time":[162,172],"to":[163,173],"progression":[165,175],"was":[166,176,180,204],"118":[167],"days,":[168],"57":[177],"days.":[178],"Toxicity":[179],"generally":[181],"mild,":[182],"asthenia":[184],"present":[185],"6":[187],"(40%)":[188],"patients.":[191],"Severe":[192],"hyponatremia":[193],"developed":[194],"two":[196],"patients,":[197],"although":[198],"association":[200],"unclear.":[205],"Conclusions:":[206],"We":[207],"concluded":[208],"this":[214,218,233],"dose":[215],"schedule":[219],"did":[220],"not":[221],"produce":[222],"significant":[223],"AIPC.":[229],"Further":[230],"development":[231],"agent":[234],"should":[240,247],"focus":[241],"on":[242],"earlier":[243],"stage":[244],"disease":[245],"it":[249],"combination":[251],"other":[253],"therapies.":[254]},"counts_by_year":[{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":5}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2016-06-24T00:00:00"}